Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 254970
License Grant
This License Agreement grants the China Licensee exclusive rights to research, develop, and commercialize the Canadian Licensors product candidates, ZW25 and ZW49. The Licensor and the Licensee have agreed to collaborate on global development of ZW25 and ZW49 in HER2-expressing solid tumors, including gastric and breast cancer.
License Property
ZW25 and ZW49 used in HER2-expressing solid tumors, including gastric and breast cancer.
Field of Use
The China Licensee will enroll patients and contribute clinical trial data from the Licensee Territory.
IPSCIO Record ID: 322039
License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.
Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.
License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.
Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.
HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.
Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.
Field of Use
The field of use is for the treatment of cancer such as breast cancer.
HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).
Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.
IPSCIO Record ID: 255299
License Grant
Licensor have entered into an exclusive collaboration and license agreement with Chinese Licensee involving three immuno-oncology (I-O) programs from Licensor's pipeline of product candidates margetuximab, MGD013 and an undisclosed multi-specific Trident molecule in preclinical development.
License Property
Margetuximab is an immune-optimized anti-HER2 monoclonal antibody currently being evaluated in Phase 3 metastatic breast cancer with anticipated topline. Margetuximab is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2, oncoprotein. HER2 is expressed by tumor cells in breast, gastric, and other solid tumor cancers, making it a key marker for biologic therapy.
MGD013 is a first-in-class bispecific DART molecule designed to provide coordinate blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for the potential treatment of a range of solid tumors and hematological malignancies.
Field of Use
Licensee is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer.
IPSCIO Record ID: 284321
License Grant
The parties agreed to have the Company develop Licensor’s pan-HER inhibitor, ARRY-543 (which the Company refers to as ASLAN001 or varlitinib), for the treatment or prevention of any disease or condition in humans, without upfront payments. Under the license agreement, the Company agreed to fund and globally develop ASLAN001 through proof of concept, initially targeting patients with gastric cancer through a development program conducted in Asia. Upon achievement of proof of concept, the Company agreed to collaborate or out-license to third parties for the further phase 3 development and commercialization.
License Property
ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
Field of Use
ARRY-543 is currently entering Phase 2 development for solid tumors.
Licensee will fund and globally develop ARRY-543 through proof of concept, initially targeting patients with gastric cancer through a development program conducted in Asia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
